The test will allow large-scale monitoring of a population’s immunity and the effectiveness of vaccines, Mount Sinai said June 14. The test measures T-cell activation and takes less than 24 hours.
“We know that vulnerable populations don’t always mount an antibody response, so measuring T-cell activation is critical to assess the full extent of a person’s immunity,” Ernesto Guccione, PhD, one of the study’s senior authors and an oncology and pharmacology professor at Mount Sinai’s Tisch Cancer Institute, said in a news release. “Additionally, the emergence of SARS-CoV-2 variants like omicron, which evade most of the neutralizing ability of antibodies, points to the need for assays that can measure T cells, which are more effective against emerging variants of concern.”
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
